Table 3.
Exact logistic regression analyses for ICI colitis (n=176)
| Variables | Univariate |
Multivariate |
||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | |
| Age | 1.03 | 0.97-1.08 | 0.371 | - | - | - |
| Male | 0.42 | 0.13-1.41 | 0.174 | 0.35 | 0.08-1.49 | 0.179 |
| Caucasian race | 11.3 | 2.37-∞ | 0.004 | 8.68 | 1.71-∞ | 0.020 |
| Ever smoker | 1.61 | 0.50-5.35 | 0.517 | - | - | - |
| Hypertension | 1.59 | 0.41-9.11 | 0.711 | - | - | - |
| Type 2 diabetes mellitus | 1.44 | 0.41-4.67 | 0.678 | - | - | - |
| Diverticulosis | 0.51 | 0.14-1.62 | 0.305 | - | - | - |
| ccRCC | 2.9 | 0.41-127.17 | 0.515 | - | - | - |
| Previous non-ICI systemic therapy | 0.51 | 0.15-2.02 | 0.378 | - | - | - |
| Duration of non-ICI systemic therapy | 1 | 0.97-1.02 | 0.722 | - | - | - |
| Previous radiation therapy | 1.58 | 0.48-6.08 | 0.585 | - | - | - |
| IMDC - Intermediate vs Favorable | 4.39 | 0.60-195.32 | 0.227 | - | - | - |
| IMDC - Poor vs Favorable | 2.7 | 0.20-148.15 | 0.728 | - | - | - |
| Combination therapy as the initial regimen | 4.71 | 1.44-16.08 | 0.009 | - | - | - |
| Any exposure to Ipilimumab | 8.91 | 1.95-83.31 | 0.002 | 7.21 | 1.46-70.63 | 0.009 |
| Non-colitis irAEs | 2.55 | 0.79-8.99 | 0.13 | 2.29 | 0.60-9.62 | 0.278 |
| Any exposure to PPIs | 5.4 | 1.18-50.55 | 0.024 | - | - | - |
| Chronic exposure to PPIs >8 weeks | 8.06 | 1.76-75.33 | 0.003 | 6.9 | 1.36-68.86 | 0.013 |
ccRCC: clear cell renal cell carcinoma, CI: confidence interval, ICI: immune checkpoint inhibitor, IMDC: international metastatic renal cell carcinoma database consortium, irAE: immune-related adverse event, OR: odds ratio, PPI: proton pump inhibitor.